The clinical significance of Mda‑7/IL‑24 and C‑myb expression in tumor tissues of patients with diffuse large B cell lymphoma

Abstract

Diffuse large B cell lymphoma (DLBCL) is the most common type of non-Hodgkin's lymphoma in adults. Mda-7/IL-24 had been identified as a differentiation inducer of B phenotype lymphoma cells. Previous studies have revealed that knockdown of C-myb also leads to the terminal differentiation of B cell lymphoma. The aim of the present study was to investigate the association between the expression of Mda-7/IL-24 and C-myb, and their prognostic significance for DLBCL patients. The tumor tissues were collected from 72 cases of DLBCL patients and detected with reverse transcription-quantitative polymerase chain reaction, western blotting and immunohistochemistry assays. The results showed that, the expression of Mda-7/IL-24 mRNA and protein was lower while the expression of C-myb was higher in DLBCL tissues, compared with the specimens of normal lymph node tissues. Furthermore, C-myb expression was negatively correlated with Mda-7/IL-24 expression at mRNA and protein levels in DLBCL tissues. The expression of Mda-7/IL-24 and C-myb in DLBCL tissues was associated with some clinicopathological parameters such as clinical stage, infiltration in bone marrow, Ki67 expression level in the tumor tissues and overall survival rates. These results indicated that low expression of Mda-7/IL-24, along with high expression of C-myb, are predictor for poor prognosis of DLBCL patients, suggesting that Mda-7/IL-24 and C-myb may be potential targets for clinical treatment of DLBCL.

Interleukin-24 Regulates T Cell Activity in Patients With Colorectal Adenocarcinoma

“…It was well accepted that IL-24 mediated cancer cell-specific death and apoptosis via multiple signaling pathways (21)(22)(23). Significantly lower IL-24 expression predicted poorer prognosis in lung adenocarcinoma (24), breast cancer (25), head and neck squamous cell carcinoma (26), and lymphoma (27,28). IL-24 high adenocarcinoma patients showed a notably higher incidence of apoptotic tumor cell death, and displayed favorable post-therapy prognosis as compared with IL-24 low patients (24).…”

Recent insights into apoptosis and toxic autophagy: The roles of MDA-7/IL-24, a multidimensional anti-cancer therapeutic

“…Additionally, tumors from patients with poor prognosis expressed lower MDA-7/IL-24 transcript levels as compared with their counterparts predicted to have good prognosis. Two recent studies analyzed MDA-7/IL-24 expression and its correlation with clinicopathological parameters and evaluated the prognostic values in hematopoietic tumors including Burkitt lymphoma and diffuse large B cell lymphoma (DLBCL) [71,72]. MDA-7/IL-24 expression was decreased in DLBCL tissues, and low expression of MDA-7/IL-24 was a predictor of poor prognosis [71].…”

“…Two recent studies analyzed MDA-7/IL-24 expression and its correlation with clinicopathological parameters and evaluated the prognostic values in hematopoietic tumors including Burkitt lymphoma and diffuse large B cell lymphoma (DLBCL) [71,72]. MDA-7/IL-24 expression was decreased in DLBCL tissues, and low expression of MDA-7/IL-24 was a predictor of poor prognosis [71]. Similar clinical correlations were found in Burkitt lymphoma where low expression of MDA-7/ IL-24 was associated with a worse clinical condition [72].…”

Prognostic Significance of Beclin 1 Expression in Diffuse Large B Cell Lymphoma Patients Receiving Immuno-chemotherapy at Zagazig University and Health Insurance Hospitals

“…In our study, Bone marrow is involved in 28.1% of cases and this is close Kim et al [23] & Park et al [26] which was 15.2% and 17.1% respectively. However, in the study by, Ma et al [27] higher proportion of Bone marrow involvement is found and represented 29.1% of cases, and this might be due to difference in sensitivity of laboratory or imaging method used to detect bone marrow involvement. The frequency of HCV infection in our patients was 18.8% of cases and this is near to Haggag et al [28] , which was 26.5% .However, In the study done by Dlouhy et al [29] carried out in spain, only 9.7% of DLBCL patients were found to have HCV infection and this might be attributed to difference in sample size and the very high prevalence of HCV infection among Egyptians.…”